Frankly, do you think therefore that Budd has to go… his shelf life has expired now that the company is supposedly in a commercial phase? He just can’t make that transition. There’s a world of difference between marketing and selling IMO. Hiring in a sales director, plus his team of 7 people is not going to be cheap or happen quickly, and not guaranteed to work either. Presumably the chairman needs to step up to the plate and find a replacement CEO before it gets to a shareholder vote to remove him from office?
I agree with other posters that the amount Budd is being paid is astonishing.
Starresnstoff… agreed it is not going to be overnight.
Do you not think Beckman would be the US distributor?
I am of the opinion that the US will adopt the test earlier rather than later. I should think hospitals would adopt to avoid lawsuits, at the very least, and as best practice for babies needing antibiotics.
I’m actually very proud to be invested in a company that is poised to do so much good. I know we shouldn’t fall in love with a share but too late for me!
Does anyone have an idea of the size of the potential market?
I think I remember a post last year saying 65m annual sales?
Anyone have an idea of the Gross profit on that? I think people on this board were saying 75- 65% Gp on the Covid test. From this distribution costs need to be deducted. I have no idea how much those are in the diagnostics industry… anyone else?
I think patience is the key here, like it has been over at Eurasia. That and trust your own research.
I’m already heavily in this share but thinking about putting more in at these ridiculous low levels. Once sales figures start to be announced for the AIhl test, as it will, the returns will be massive.
Caveman, I’m in a very similar situation to you. I’m continuing to hold as I think this is a great company with fantastic products that will sell. I’m lucky that I don’t need to access the funds. At the very worst I think the company will be bought out if it cannot monetise it’s pipeline. However we have all seen what happens to the share price when there is good news. So I’m being patient and am confident that this will come good, and some.
I’m not sure I follow all that … but the US defence specifically mentions and includes a Genedrive product in its budget proposal for 2022. Is this the handheld POC device that is still in development?
Andrew Marr interviewing Sir Peter Horby, chair of NERVTAG, said that despite being double- jabbbed, he contracted the coronavirus last week and that it was very unpleasant. He said that the symptoms to start with were more like a summer cold and he didn’t suspect it was covid.
Sir Peter said that the vaccines are very effective at preventing hospitalisation and deaths, but not necessarily infections. Sir Peter also said that this winter there is increased susceptibility to flu in the population, as there was very little flu last year. And that immunity will decline over time to those vaccinated against the virus.
Putting this together I can see that testing will continue to be needed in huge numbers to keep the country going. The first sign of a cold people will be wanting to get tested. With a new health secretary in place hopefully he will use a sovereign test this time round.
RE: Results in: Happy v OverTheMoon (repost)26 Jun 2021 13:44
Remember that dividends are paid out after tax… not sure what the capital gains tax or corporation tax is in Russia…and there’ll be all the professional fees to be paid, and money retained for working capital for the retained assets. The company will not be paying out 100% of the sale proceeds. But even so it will be hefty and I believe equal at least to the share price to totally derail our investments .
Hi Mike, The Companies Act will make sure that the results of the new subsidiary are included in the EUA group accounts. It’s very much included and transparent in law. It’s not a stand alone company that will go under the radar. Best, Midsummer